3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
12
Gastrointestinal
4
Breast
4
Sarcoma
2
Lymphoid
1
Head & Neck
1
Gynecologic
1
Conditions
Lymphoma, T-Cell, Cutaneous
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Interventions
Rituximab
702
Cyclophosphamide
645
Vincristine
353
Doxorubicin
309
Etoposide
305
Cytarabine
271
Filgrastim
250
Prednisone
249
Methotrexate
241
fludarabine phosphate
231
Dexamethasone
209
fludarabine
184
Peripheral Blood Stem Cell Transplantation
166
Radiotherapy
161
Granulocyte Colony-Stimulating Factor
145
Lenalidomide
144
Bendamustine Hydrochloride
142
Bortezomib
127
Melphalan
126
ibrutinib
111
Busulfan
111
Mycophenolic Acid
108
Whole-Body Irradiation
107
Tacrolimus
96
Cyclosporine
87
Gemcitabine
82
Ifosfamide
80
Calcium Dobesilate
80
Alemtuzumab
80
Leucovorin
78
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
talimogene laherparepvec
×
Lymphoid
×
Clear all
NCT03458117
2022-03-18
20139157 T-VEC
University of Zurich
Phase 1
Completed
26 enrolled